Results 11 to 20 of about 22,026 (259)

Estimating the Effects of Continuous Albuterol Dosage on Clinical Outcomes for Pediatric Critical Asthma Exacerbation: A Retrospective Cohort Study. [PDF]

Pediatr Pulmonol
Riggins DP, Mendonca EA, Bulgarelli L, Tachinardi P, Tu W, Rogerson C.   +5 more
europepmc   +3 more sources

A randomized, masked, crossover, clinical trial of the efficacy and safety of nebulized albuterol sulfate and dexamethasone sodium phosphate in asthmatic horses. [PDF]

J Vet Intern Med
Tyson KN, Couetil LL, Ivester KM, Murray L, Mukhopadhyay A, Marmolejo JF, Jannasch A.   +6 more
europepmc   +2 more sources

Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol [PDF]

Journal of Allergy and Clinical Immunology, 2001
Henry Milgrom, David P. Skoner, George Bensch, Kenneth T. Kim, Raymond Claus, Rudolf A. Baumgartner   +5 more
exaly   +2 more sources

Dexmedetomidine as an adjunctive treatment for acute asthma [PDF]

Clinical and Experimental Emergency Medicine, 2021
Objective This study aimed to compare the efficacy of using dexmedetomidine with salbutamol and salbutamol nebulization alone in patients with acute exacerbation of asthma presenting to the emergency department.
Hassan Motamed, Arash Forouzan, Meisam Moezzi, Hossein Alizadeh   +3 more
doaj   +1 more source

Comparison of Regularly Scheduled with As-Needed Use of Albuterol in Mild Asthma [PDF]

New England Journal of Medicine, 1996
Elliot Israel, Vernon M Chinchilli, Stanley J Szefler   +2 more
exaly   +2 more sources

Ipratropium/Albuterol [PDF]

, 2020
National Cancer Institute
openaire   +2 more sources

Association between dispensing of low-value oral albuterol and removal from Medicaid preferred drug lists

BMC Health Services Research, 2022
Background Oral albuterol has worse efficacy and side effects compared with inhaled albuterol, and thus its use has been discouraged for decades. Drug inclusion or exclusion on formularies have been associated with reductions in low-value care.
Anna Volerman, Alison Pelczar, Rena Conti, Christina Ciaccio, Kao-Ping Chua   +4 more
doaj   +1 more source

β2-Agonists inhibit TNF-α-induced ICAM-1 expression in human airway parasympathetic neurons. [PDF]

PLoS ONE, 2012
Major basic protein released from eosinophils to airway parasympathetic nerves blocks inhibitory M(2) muscarinic receptors on the parasympathetic nerves, increasing acetylcholine release and potentiating reflex bronchoconstriction.
Zhenying Nie, Allison D Fryer, David B Jacoby   +2 more
doaj   +1 more source

Epigenomic response to albuterol treatment in asthma-relevant airway epithelial cells

Clinical Epigenetics, 2023
Background Albuterol is the first-line asthma medication used in diverse populations. Although DNA methylation (DNAm) is an epigenetic mechanism involved in asthma and bronchodilator drug response (BDR), no study has assessed whether albuterol could ...
Javier Perez-Garcia, Maria Pino-Yanes, Elizabeth G. Plender, Jamie L. Everman, Celeste Eng, Nathan D. Jackson, Camille M. Moore, Kenneth B. Beckman, Vivian Medina, Sunita Sharma, Daniel Efrain Winnica, Fernando Holguin, José Rodríguez-Santana, Jesús Villar, Elad Ziv, Max A. Seibold, Esteban G. Burchard   +16 more
doaj   +1 more source

Effects of the ß2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravis. [PDF]

PLoS ONE, 2014
The β2-adrenergic receptor agonist, albuterol, has been reported beneficial in treating several forms of congenital myasthenia. Here, for the first time, we examined the potential benefit of albuterol in a mouse model of anti-Muscle Specific Kinase (MuSK)
Nazanin Ghazanfari, Marco Morsch, Nigel Tse, Stephen W Reddel, William D Phillips   +4 more
doaj   +1 more source